Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Insuring physical AI: Robotics reshaping risk and liability
As AI moves from software into the physical world, risk evolves. Physical AI introduces new questions around liability, governance and insurability fo
Demystifying life actuarial technology
MCP connects AI agents to tools and data, while agent-to-agent architectures let specialist AI systems collaborate, helping make actuarial technology
Why salary sacrifice remains a powerful tool in DC pensions
The proposed cap on salary sacrifice contributions for workplace pension savers caused more concern than may have been warranted. The annual threshold

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.